Doctors checking a soon-to-be-unveiled federal website that will publicly list drug company payments are encountering error messages if they have not accepted industry money.
by Charles Ornstein, ProPublica
The federal government has a word for physicians who don't have financial relationships with pharmaceutical and medical device manufacturers: "Error."
Botox-maker Allergan announces restructuring measures that will cut 13% of its global workforce as the company sinks deeper into a months-long battle against activist investors and attempts at a takeover.
Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan's earnings.
Activist investor Bill Ackman urges shareholders to take action before time runs out on Valeant Pharmaceuticals' hostile $53 billion bid to acquire Allergan.
Abbott agrees to deal its specialty and branded generic pharmaceutical line to Mylan for $5.3 billion.
Stryker Corp. agrees to sell its bone morphogenetic protein-7 assets to Mariel Therapeutics, which plans to investigate BMP-7 as a possible treatment for a variety of conditions.
Another hedge fund buys a massive stake in Botox-maker Allergan, throwing its support behind Valeant Pharmaceuticals' unrequited acquisition bid, according to a report.
Another player entered the arena in the running saga over Allergan (NYSE:AGN) as hedge fund Paulson & Co bought up a huge chunk of the Botox-maker's shares, according to Reuters.
Valeant Pharmaceuticals makes its promised hostile play in a $53 billion attempt to take over Botox-maker Allergan.
Valeant Pharmaceuticals is preparing to officially launch its long-promised hostile takeover bid for Allergan (NYSE:AGN), aiming to solicit support from Allergan shareholders to host a special meeting outside of the company's control.